|
1
|
Stacchiotti S, Casali PG, Lo Vullo S, et
al: Chordoma of the mobile spine and sacrum: a retrospective
analysis of a series of patients surgically treated at two referral
centers. Ann Surg Oncol. 17:211–219. 2010. View Article : Google Scholar
|
|
2
|
DeLaney TF, Liebsch NJ, Pedlow FX, et al:
Phase II study of high-dose photon/proton radiotherapy in the
management of spine sarcomas. Int J Radiat Oncol Biol Phys.
74:732–739. 2009. View Article : Google Scholar :
|
|
3
|
Zhou H, Chen CB, Lan J, et al:
Differential proteomic profiling of chordomas and analysis of
prognostic factors. J Surg Oncol. 102:720–727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wisniewski JR, Zougman A, Nagaraj N and
Mann M: universal sample preparation method for proteome analysis.
Nat Methods. 6:359–362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vogel C and Marcotte EM: Calculating
absolute and relative protein abundance from mass
spectrometry-based protein expression data. Nat Protoc.
3:1444–1451. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu P, Vogel C, Wang R, Yao X and Marcotte
EM: Absolute protein expression profiling estimates the relative
contributions of transcriptional and translational regulation. Nat
Biotechnol. 25:117–124. 2007. View
Article : Google Scholar
|
|
7
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate - a practical and powerful approach to
multiple testing. J R Stat Soc B. 57:289–300. 1995.
|
|
8
|
Conesa A, Gotz S, Garcia-Gomez JM, Terol
J, Talon M and Robles M: Blast2GO: a universal tool for annotation,
visualization and analysis in functional genomics research.
Bioinformatics. 21:3674–3676. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamada T, Letunic I, Okuda S, Kanehisa M
and Bork P: IPath2.0: interactive pathway explorer. Nucleic Acids
Res. 39:W412–W415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimizu-Hirota R, Sasamura H, Kuroda M,
Kobayashi E and Saruta T: Functional characterization of podocan, a
member of a new class in the small leucine-rich repeat protein
family. FEBS Lett. 563:69–74. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoover KB, Liao SY and Bryant PJ: Loss of
the tight junction MAGUK ZO-1 in breast cancer: relationship to
glandular differentiation and loss of heterozygosity. Am J Pathol.
153:1767–1773. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu W, Liu B, Xin L, Zhang Y, Chen X, Zhu
Z and Lin Y: Downregulated expression of complement factor I: a
potential suppressive protein for gastric cancer identified by
serum proteome analysis. Clin Chim Acta. 377:119–126. 2007.
View Article : Google Scholar
|
|
13
|
Ohnuma SI: Cancer diagnosis and treatment.
Google Patents. 2011
|
|
14
|
Ostrow KL, Park HL, Hoque MO, et al:
Pharmacologic unmasking of epigenetically silenced genes in breast
cancer. Clin Cancer Res. 15:1184–1191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tachezy M, Zander H and Wolters-Eisfeld G:
Activated leukocyte cell adhesion molecule (CD166): an ‘inert’
cancer stem cell marker for non-small cell lung cancer? Stem Cells.
32:1429–1436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ibrahim SA, Reed KR, Clarke AR, Pritchard
DM and Jenkins JR: Sa1992 SFRS2 and CDC5L interaction: an insight
into downstream events following APC deletion during colorectal
carcinogenesis. Gastroenterology. 144:S353–S354. 2013.
|
|
17
|
Palmieri D, Bouadis A, Ronchetti R, Merino
MJ and Steeg PS: Rab11a differentially modulates epidermal growth
factor-induced proliferation and motility in immortal breast cells.
Breast Cancer Res Treat. 100:127–137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Klement RJ and Kammerer U: Is there a role
for carbohydrate restriction in the treatment and prevention of
cancer? Nutr Metab. 8:752011. View Article : Google Scholar
|
|
19
|
Walenta S, Wetterling M, Lehrke M,
Schwickert G, Sundfør K, Rofstad EK and Mueller-Klieser W: High
lactate levels predict likelihood of metastases, tumor recurrence,
and restricted patient survival in human cervical cancers. Cancer
Res. 60:916–921. 2000.PubMed/NCBI
|
|
20
|
Seyfried TN and Shelton LN: Cancer as a
metabolic disease. Nutr Metab. 7:72010. View Article : Google Scholar
|
|
21
|
Skonier JE, Bowen MA, Emswiler J, Aruffo A
and Bajorath J: Recognition of diverse proteins by members of the
immunoglobulin superfamily: delineation of the receptor binding
site in the human CD6 ligand ALCAM. Biochemistry. 35:12287–12291.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weidle HU, Eggle D, Klostermann S and
Swart GW: ALCAM/CD166: cancer-related issues. Cancer Genom Proteom.
7:231–243. 2010.
|
|
23
|
Van Kilsdonk JW, Wilting RH, Bergers M,
van Muijen GN, Schalkwijk J, van Kempen LL and Swart GW:
Attenuation of melanoma invasion by a secreted variant of activated
leukocyte cell adhesion molecule. Cancer Res. 68:3671–3679. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ofori-Acquah SF and King JA: Activated
leukocyte cell adhesion molecule: a new paradox in cancer. Transl
Res. 151:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ihnen M, Müller V, Wirtz RM, et al:
Predictive impact of activated leukocyte cell adhesion molecule
(ALCAM/CD166) in breast cancer. Breast Cancer Res Treat.
112:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mezzanzanica D, Fabbi M, Bagnoli M, et al:
Subcellular localization of activated leukocyte cell adhesion
molecule is a molecular predictor of survival in ovarian carcinoma
patients. Clin Cancer Res. 14:1726–1733. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tachezy M, Zander H, Marx AH, Stahl PR,
Gebauer F, Izbicki JR and Bockhornet M: ALCAM (CD166) expression
and serum levels in pancreatic cancer. PLoS One. 7:e390182012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tachezy M, Effenberger K, Zander H, et al:
ALCAM (CD166) expression and serum levels are markers for poor
survival of esophageal cancer patients. Int J Cancer. 131:396–405.
2012. View Article : Google Scholar
|
|
29
|
Tachezy M, Zander H, Gebauer F, Marx A,
Kaif JT, Izbicki JR and Bockhorn M: Activated leukocyte cell
adhesion molecule (CD166) - its prognostic power for colorectal
cancer patients. J Surg Res. 177:e15–e20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tachezy M, Zander H, Marx AH, et al: ALCAM
(CD166) expression as novel prognostic biomarker for pancreatic
neuroendocrine tumor patients. J Surg Res. 170:226–232. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ishiguro F, Murakami H, Mizuno T, et al:
Membranous expression of activated leukocyte cell adhesion molecule
contributes to poor prognosis and malignant phenotypes of
non-small-cell lung cancer. J Surg Res. 179:24–32. 2013. View Article : Google Scholar
|
|
32
|
Simon R, Mirlacher M and Sauter G:
Immunohistochemical analysis of tissue microarrays. Methods Mol
Biol. 664:113–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
